South Africa’s Afrigen Biologics has used the publicly available sequence of Moderna’s COVID-19 mRNA vaccine to make its own version of the shot, which could be tested in humans before the end of this year. The vaccine candidate would be the first to be made based on a widely used vaccine without the assistance and approval of the developer. The World Health Organization (WHO) last year picked a consortium, including Afrigen, for a pilot project to give poor and middle-income countries the know-how to make COVID-19 vaccines, after market leaders of the mRNA COVID vaccine, Pfizer, BioNTech, and Moderna, declined a WHO request to share their technology and expertise.The WHO and partners hope the hub will help overcome glaring inequalities between rich nations and poorer countries in accessing vaccine doses, with 99 percent of all of Africa’s vaccines imported and the negligible remainder manufactured locally. Biovac, a partly state-owned South African vaccine producer, will be the first recipient of the technology from the hub. Afrigen has also agreed to help train companies in Argentina and Brazil.
SOURCE: AL JAZEERA
A Great Recognition for the Work of Female Peace Builders in Cameroon
Could An Online Gathering Solve South Africa’s Putin Problem?
Calls For African Countries to Create Champions in Key Sectors
Times Higher Education Impact Ranks University of Johannesburg as on Track to Reach SDGs
Ghana’s Appetite for Hand-me-downs Ends Up in Crucial Waterways
Lilongwe is Taking a Closer Look at Who is Granted Asylum
Tanzania and Australia Forge Closer Ties in the Mining and Energy Industries
Kenyans Bemoan Plans to Raise Taxes
Building a Dynamic Ecosystem of Innovative Entrepreneurs and Startups in Libya
What Happened to Cause Musicians to Leave Ethiopia?
Rukky Ladoja & Building a Responsible Nigerian Fashion Brand
How to Write About Africa: Collected Works’ Shows Binyavanga Wainaina’s Legacy